Skip to main content
. 2016 Feb 23;68(3):299–307. doi: 10.1002/acr.22676

Figure 2.

Figure 2

Mean change from baseline in the Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28[ESR]) over time by baseline methotrexate (MTX) dose category (intent‐to‐treat population; MTX 2‐dose categorization). A, placebo plus MTX, B, certolizumab pegol (CZP) 200 mg plus MTX, and C, CZP 400 mg plus MTX. Week 24 interaction P value = 0.119 (MTX <15 mg/week vs. MTX ≥15 mg/week across treatment groups, based on analysis of covariance).